Core Viewpoint - The sudden passing of Liu Zhonghua, a core founder and key executive of Shuoshi Biotechnology, raises concerns about the company's future amidst industry challenges and operational pressures [2][5][6] Company Overview - Shuoshi Biotechnology was founded in 2010, focusing on infectious disease testing and maternal and child health [5] - The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments, adopting an integrated business model of "reagents + instruments + services" [5] Leadership and Contributions - Liu Zhonghua was a molecular biology expert and had a significant role in the company's development, serving as a technical director and vice president from 2010 to 2017, and as a board member since 2017 [5][6] - He voluntarily reduced his salary by 40% recently to support the company's operational efficiency [6] - Liu held 2.57% of the company's total shares, amounting to 2.15 million shares [5] Recent Company Performance - Shuoshi Biotechnology is currently facing performance pressures due to industry adjustments [6] - The company recently implemented voluntary salary reductions among its executives to optimize operational costs and improve management efficiency [6] Board Composition - Following Liu Zhonghua's passing, the board of directors has decreased from 9 to 8 members, which is still above the legal minimum but below the number stipulated in the company's articles of association [6] - The company plans to complete the board member replacement process in accordance with legal procedures [6]

Group 1 - The company, Shuoshi Biotechnology, announced the passing of its board member and vice president, Liu Zhonghua, due to sudden illness on September 12, 2025, at the age of 56 [1][3] - Liu Zhonghua was a core founder of Shuoshi Biotechnology and had recently voluntarily reduced his salary by 40% to support the company's operations [3][9] - The company focuses on the research, production, and sales of in vitro diagnostic products, particularly in the fields of infectious disease testing and maternal and child health [7][8] Group 2 - Liu Zhonghua held a Ph.D. from Xi'an Jiaotong University and was recognized as an expert in molecular biology, contributing significantly to the company's development [7][8] - Following Liu's passing, the board of directors will decrease from 9 to 8 members, which does not affect the normal operation of the board but is below the number stipulated in the company's articles of association [9] - The company plans to complete the board member replacement process in accordance with legal procedures and will fulfill its information disclosure obligations [9]

Core Points - The company announced the unfortunate passing of its director and vice president, Liu Zhonghua, due to sudden illness on September 12, 2025, expressing deep condolences and respect for his contributions [1][2] - Liu Zhonghua held 2,152,512 shares of the company, representing 2.57% of the total share capital, and the company will follow legal procedures regarding his shares [2] - Following his death, the board of directors will reduce from 9 to 8 members, which does not affect the normal operation but is below the number stipulated in the company's articles of association, prompting a need for a board member replacement [2]

Core Viewpoint - The sudden passing of Liu Zhonghua, a core founder and key executive of Shuoshi Biological, raises concerns about the company's future operations and governance structure [1][6][7] Company Overview - Shuoshi Biological was founded in 2010, focusing on infectious disease testing and maternal and child health [5] - The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments, adopting an integrated business model of "reagents + instruments + services" [5] Leadership and Contributions - Liu Zhonghua served as a technical director and vice president from August 2010 to March 2017, and as a board member from March 2011 to March 2017 [6] - He held the position of director, technical director, and vice president of the listed company since March 2017 [6] - Liu was recognized for his dedication to the development of diagnostic products related to infectious diseases and maternal and child health, receiving multiple honors including "Outstanding Communist Party Member of Jiangsu Province" and "National Model Worker" [6] Shareholding and Governance - Liu Zhonghua directly held 2.57% of the company's total shares, amounting to 2.15 million shares [6] - Following his passing, the board of directors decreased from 9 to 8 members, which is still above the legal minimum but below the number stipulated in the company's articles of association [7] - The company plans to complete the board member replacement process in accordance with legal procedures [7] Financial Context - The company is currently facing performance pressure due to industry adjustments [7] - In response to external pressures, the company's executives, including Liu Zhonghua, voluntarily reduced their salaries, with Liu's salary cut by 40% [7] - Liu's reported compensation for the previous year was 1.5162 million yuan [7]

Core Points - Liu Zhonghua, the Vice President of Shuoshi Biotechnology, passed away due to sudden illness on September 12, 2025, at the age of 56 [1] - Liu was a core founder of the company and made significant contributions to its establishment and growth, particularly in the fields of infectious disease testing, cancer screening, and maternal and child health diagnostics [1][2] - Liu held a Ph.D. from Xi'an Jiaotong University and was an expert in molecular biology, with a career that included research at the Chinese Academy of Medical Sciences and collaborations in the U.S. [1] Company Impact - Following Liu's death, the board of directors of Shuoshi Biotechnology decreased from 9 to 8 members, which does not affect the normal operation of the board but is below the number stipulated in the company's articles of association [2] - The company will conduct a board member replacement process in accordance with the Company Law of the People's Republic of China and its articles of association [2] - Liu directly held 2.57% of the company's total shares, amounting to 2.1525 million shares, which will be handled according to relevant laws and regulations [2]

Core Points - Liu Zhonghua, the Vice President of Shuoshi Biotechnology, passed away due to sudden illness on September 12, 2025, at the age of 56 [2] - Liu was a core founder of the company and made significant contributions to its establishment and growth, particularly in the fields of infectious disease testing, cancer screening, and maternal and child health diagnostics [4][5] - Liu held a Ph.D. from Xi'an Jiaotong University and was an expert in molecular biology, with a career that included research at the Chinese Academy of Medical Sciences and collaborations in the U.S. [4] - Following Liu's death, the board of directors of Shuoshi Biotechnology decreased from 9 to 8 members, which does not affect the normal operation of the board but is below the number stipulated in the company's articles of association [5]

Core Points - The company announced the passing of its Vice President Liu Zhonghua due to sudden illness on September 12, 2025, at the age of 56 [1] - Liu Zhonghua was a molecular biology expert in China, with a focus on virology and molecular biology research [1] - He had previously worked at the Chinese Academy of Medical Sciences and conducted collaborative research in the United States from 2008 to 2009 before joining the company in 2010 [1]

证券代码：688399 证券简称：硕世生物 公告编号：2025-033 江苏硕世生物科技股份有限公司 关于公司董事、副总经理逝世的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）沉痛公告，公司董事、 副总经理刘中华先生因突发疾病于 2025 年 9 月 12 日晨不幸逝世。公司及全体员 工对此表示深切的哀悼，并向其家属致以诚挚的慰问。 江苏硕世生物科技股份有限公司 董事会 2025 年 9 月 13 日 刘中华先生始终秉持实业报国的信念，积极践行社会责任，将毕生心力奉献 于传染病检测、肿瘤筛查及妇幼健康相关诊断产品的研发事业。他曾荣获江苏省 优秀共产党员、江苏省新冠肺炎疫情防控先进个人、全国劳动模范等多项荣誉。 作为公司核心创始人之一，他多年恪尽职守、勤勉奉献，为公司的创立与成长作 出了不可磨灭的贡献。在担任公司董事及副总经理期间，他勤勉务实、履职尽责， 对公司发展起到了重要的推动作用。公司及全体员工谨向刘中华先生致以崇高敬 意和衷心感谢。 截至本公告披露日，刘中华先生直接 ...

Company Overview - Jiangsu Shuoshi Biological Technology Co., Ltd. is located at 837 Yaochedada, Taizhou, Jiangsu Province, established on April 12, 2010, and listed on December 5, 2019. The company specializes in the research, production, and sales of in vitro diagnostic reagents and related testing instruments [1] - The main business revenue composition includes: testing reagents 85.89%, purchased instruments and materials 7.19%, testing instruments 3.84%, testing services 2.24%, and others 0.84% [1] Stock Performance - On September 12, Shuoshi Biological's stock rose by 5.1%, reaching a price of 65.98 yuan per share, with a trading volume of 124 million yuan and a turnover rate of 2.29%. The total market capitalization is 5.534 billion yuan [1] Shareholder Information - Among the top ten circulating shareholders of Shuoshi Biological, one fund from Huaxia Fund holds a significant position. Huaxia Industry Prosperity Mixed Fund (003567) increased its holdings by 1.0079 million shares in the second quarter, totaling 2.2546 million shares, which accounts for 2.69% of the circulating shares. The estimated floating profit today is approximately 7.2148 million yuan [2] - Huaxia Industry Prosperity Mixed Fund (003567) was established on February 4, 2017, with a latest scale of 7.261 billion yuan. Year-to-date returns are 49.16%, ranking 881 out of 8174 in its category; the one-year return is 99.56%, ranking 463 out of 7981; and since inception, the return is 357.78% [2]

Core Viewpoint - The IVD industry is facing significant challenges, leading to salary reductions among executives and a general downturn in performance across the sector [2][4][7]. Company Summary - The company, Shuoshi Biological, has announced voluntary salary reductions for its executives due to ongoing economic and industry challenges, aiming to optimize operational costs and enhance management efficiency [2]. - The core executive team's salaries will be significantly reduced starting August 15, 2025, with the chairman's and general manager's salaries cut by 50% [4]. - The company's revenue for the first half of 2025 was 176 million yuan, a slight decrease of 1.05% year-on-year, while net profit dropped by 86.35% to 3.99 million yuan [4][5]. - The company experienced explosive growth during the pandemic, with revenue peaking at 5.535 billion yuan in 2022, but has since declined to 403 million yuan in 2023 and is projected to fall further to 349 million yuan in 2024 [4][5]. Industry Summary - The IVD industry has entered a downward cycle since peaking in 2022, with over 40 out of 60 publicly listed companies reporting declines in both revenue and net profit in the first half of 2025 [7]. - Price pressures from centralized procurement have significantly impacted profit margins, with average price reductions of 77% to 92% reported in certain regions [7]. - The implementation of mutual recognition of test results among medical institutions has reduced the demand for repeated testing, further decreasing the consumption of testing reagents [7]. - The company is exploring overseas markets as a potential solution to domestic challenges, with plans to establish international marketing teams and diversify sales channels [8]. - Despite a 31.32% year-on-year increase in overseas revenue to 693,420 yuan, it still represents only 3.95% of total revenue [8].